Plasma Microbial Cell-free DNA Next-generation Sequencing in the Diagnosis and Management of Febrile Neutropenia.
Febrile neutropenia
infection
next-generation sequencing
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
03 05 2022
03 05 2022
Historique:
received:
03
11
2020
pubmed:
20
4
2021
medline:
10
5
2022
entrez:
19
4
2021
Statut:
ppublish
Résumé
Standard testing fails to identify a pathogen in most patients with febrile neutropenia (FN). We evaluated the ability of the Karius microbial cell-free DNA sequencing test (KT) to identify infectious etiologies of FN and its impact on antimicrobial management. This prospective study (ClinicalTrials.gov; NCT02912117) enrolled and analyzed 55 patients with FN. Up to 5 blood samples were collected per subject within 24 hours of fever onset (T1) and every 2 to 3 days. KT results were compared with blood culture (BC) and standard microbiological testing (SMT) results. Positive agreement was defined as KT identification of ≥1 isolate also detected by BC. At T1, positive and negative agreement were 90% (9/10) and 31% (14/45), respectively; 61% of KT detections were polymicrobial. Clinical adjudication by 3 independent infectious diseases specialists categorized Karius results as: unlikely to cause FN (N = 0); definite (N = 12): KT identified ≥1 organism also found by SMT within 7 days; probable (N = 19): KT result was compatible with a clinical diagnosis; possible (N = 10): KT result was consistent with infection but not considered a common cause of FN. Definite, probable, and possible cases were deemed true positives. Following adjudication, KT sensitivity and specificity were 85% (41/48) and 100% (14/14), respectively. Calculated time to diagnosis was generally shorter with KT (87%). Adjudicators determined real-time KT results could have allowed early optimization of antimicrobials in 47% of patients, by addition of antibacterials (20%) (mostly against anaerobes [12.7%]), antivirals (14.5%), and/or antifungals (3.6%); and antimicrobial narrowing in 27.3% of cases. NCT02912117. KT shows promise in the diagnosis and treatment optimization of FN.
Sections du résumé
BACKGROUND
Standard testing fails to identify a pathogen in most patients with febrile neutropenia (FN). We evaluated the ability of the Karius microbial cell-free DNA sequencing test (KT) to identify infectious etiologies of FN and its impact on antimicrobial management.
METHODS
This prospective study (ClinicalTrials.gov; NCT02912117) enrolled and analyzed 55 patients with FN. Up to 5 blood samples were collected per subject within 24 hours of fever onset (T1) and every 2 to 3 days. KT results were compared with blood culture (BC) and standard microbiological testing (SMT) results.
RESULTS
Positive agreement was defined as KT identification of ≥1 isolate also detected by BC. At T1, positive and negative agreement were 90% (9/10) and 31% (14/45), respectively; 61% of KT detections were polymicrobial. Clinical adjudication by 3 independent infectious diseases specialists categorized Karius results as: unlikely to cause FN (N = 0); definite (N = 12): KT identified ≥1 organism also found by SMT within 7 days; probable (N = 19): KT result was compatible with a clinical diagnosis; possible (N = 10): KT result was consistent with infection but not considered a common cause of FN. Definite, probable, and possible cases were deemed true positives. Following adjudication, KT sensitivity and specificity were 85% (41/48) and 100% (14/14), respectively. Calculated time to diagnosis was generally shorter with KT (87%). Adjudicators determined real-time KT results could have allowed early optimization of antimicrobials in 47% of patients, by addition of antibacterials (20%) (mostly against anaerobes [12.7%]), antivirals (14.5%), and/or antifungals (3.6%); and antimicrobial narrowing in 27.3% of cases.
CLINICAL TRIALS REGISTRATION
NCT02912117.
CONCLUSION
KT shows promise in the diagnosis and treatment optimization of FN.
Identifiants
pubmed: 33870413
pii: 6236109
doi: 10.1093/cid/ciab324
pmc: PMC9070798
doi:
Substances chimiques
Anti-Bacterial Agents
0
Cell-Free Nucleic Acids
0
Banques de données
ClinicalTrials.gov
['NCT02912117']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1659-1668Commentaires et corrections
Type : CommentIn
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America.
Références
Proc Natl Acad Sci U S A. 2015 Oct 27;112(43):13336-41
pubmed: 26460048
Transfusion. 2016 May;56(5):1138-47
pubmed: 26865079
Pediatr Blood Cancer. 2019 Jul;66(7):e27734
pubmed: 30941906
Clin Infect Dis. 2021 Jan 27;72(2):239-245
pubmed: 31942944
J Natl Compr Canc Netw. 2016 Jul;14(7):882-913
pubmed: 27407129
Ther Adv Infect Dis. 2013 Feb;1(1):37-43
pubmed: 25165543
Clin Infect Dis. 2012 Oct;55(7):905-14
pubmed: 22718773
J Clin Microbiol. 2010 Oct;48(10):3510-6
pubmed: 20720024
Diagn Microbiol Infect Dis. 2018 Nov;92(3):210-213
pubmed: 30017314
Open Forum Infect Dis. 2019 Aug 1;6(8):
pubmed: 31375834
Expert Rev Mol Diagn. 2018 Jul;18(7):605-615
pubmed: 29898605
Open Forum Infect Dis. 2016 Jul 12;3(3):ofw144
pubmed: 27704003
Curr Opin Infect Dis. 2013 Aug;26(4):332-7
pubmed: 23806896
Nat Microbiol. 2019 Apr;4(4):663-674
pubmed: 30742071
PLoS One. 2015 Aug 13;10(8):e0135756
pubmed: 26270467
Open Forum Infect Dis. 2019 Jun 01;6(6):ofz242
pubmed: 31249846
BMC Microbiol. 2014 Dec 11;14:313
pubmed: 25551203
Curr Opin Infect Dis. 2019 Aug;32(4):295-299
pubmed: 31169551
Clin Infect Dis. 2004 Jul 15;39 Suppl 1:S32-7
pubmed: 15250018
Virulence. 2016 Apr 2;7(3):280-97
pubmed: 27002635
BMC Infect Dis. 2019 May 2;19(1):371
pubmed: 31046692
Ann Oncol. 2010 May;21 Suppl 5:v252-6
pubmed: 20555092
Sci Rep. 2016 Mar 21;6:23532
pubmed: 26996149
Clin Infect Dis. 2008 Jun 15;46(12):1813-21
pubmed: 18462102
Annu Rev Pathol. 2019 Jan 24;14:319-338
pubmed: 30355154